vertex journavx - Search News

Vertex Pharma Stock Surges

New pain drug, Vertex’s Journavx, gets FDA approval as safer alternative to addictive opioids

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, surgeries, and other injuries and procedures.

Seeking Alpha · 2h

Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug

Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.

Pharm Exec · 2h

FDA Approves Vertex Pharmaceuticals’ First-in-Class Non-Opioid Journavx for Moderate-to-Severe Acute Pain

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

20h

Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...

6h

What's Happening With VRTX Stock?

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results